BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.

Mikael CohenLydiane MondotFlorence BucciarelliBéatrice PignoletDavid-Axel LaplaudSandrine WiertlewskiBruno BrochetAurélie RuetGilles DeferNathalie DerachePatrick VermerschHélène ZephirMarc DebouverieGuillaume MatheyEric BergerChrystelle CappéPierre LabaugeClarisse Carra DallièreJérôme De SezeKévin BigautDavid BrassatChristine Lebrun-Frenay

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)

BEST-MS is a prospective study that compared head-to-head the effectiveness of NTZ and FTY in active relapsing-remitting MS. Our results suggest a superiority of NTZ over FTY.

Keyphrases

multiple sclerosis
optic nerve
mass spectrometry
ms ms
randomized controlled trial
systematic review
disease activity